Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Amortization - Intangibles: 2017-2025

Historic Amortization - Intangibles for Adma Biologics (ADMA) over the last 9 years, with Sep 2025 value amounting to $38,000.

  • Adma Biologics' Amortization - Intangibles rose 35.71% to $38,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $132,000, marking a year-over-year decrease of 76.00%. This contributed to the annual value of $400,000 for FY2024, which is 44.75% down from last year.
  • Adma Biologics' Amortization - Intangibles amounted to $38,000 in Q3 2025, which was up 18.75% from $32,000 recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Amortization - Intangibles ranged from a high of $200,000 in Q1 2021 and a low of $25,000 during Q1 2025.
  • Over the past 3 years, Adma Biologics' median Amortization - Intangibles value was $142,000 (recorded in 2024), while the average stood at $116,545.
  • Examining YoY changes over the last 5 years, Adma Biologics' Amortization - Intangibles showed a top increase of 35.71% in 2025 and a maximum decrease of 87.05% in 2025.
  • Adma Biologics' Amortization - Intangibles (Quarterly) stood at $178,486 in 2021, then remained steady at $178,486 in 2022, then rose by 4.77% to $187,000 in 2023, then slumped by 80.21% to $37,000 in 2024, then spiked by 35.71% to $38,000 in 2025.
  • Its last three reported values are $38,000 in Q3 2025, $32,000 for Q2 2025, and $25,000 during Q1 2025.